Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

1,246.17
-9.2300-0.74%
Volume:1.01M
Turnover:1.26B
Market Cap:1.18T
PE:41.83
High:1,262.14
Open:1,262.14
Low:1,230.98
Close:1,255.40
52wk High:1,292.65
52wk Low:694.23
Shares:945.38M
Float Shares:939.00M
Volume Ratio:0.54
T/O Rate:0.11%
Dividend:6.69
Dividend Rate:0.54%
EPS(TTM):29.79
EPS(LYR):22.95
ROE:102.29%
ROA:20.36%
PB:34.77
PE(LYR):54.30

Loading ...

Eli Lilly Wins Full FDA Approval for Selpercatinib in Solid Tumors

MT Newswires Live
·
Jul 15

Retevmo granted FDA traditional approval for RET fusion-positive solid tumors

TIPRANKS
·
Jul 15

FDA Grants Traditional Approval to Selpercatinib for Locally Advanced or Metastatic Ret Fusion-positive Solid Tumors

THOMSON REUTERS
·
Jul 15

Eli Lilly is Maintained at Outperform by Bernstein

Dow Jones
·
Jul 14

Eli Lilly : Bernstein Raises Target Price to $1385 from $1300

THOMSON REUTERS
·
Jul 14

Movement Alert|Eli Lilly Falls 3.11% in Regular Trading, Patent Lawsuit Restart Compounds Sector-Wide Profit-Taking

Market Focus
·
Jul 14

Eli Lilly and Co Stock (LLY) Moved Down by 3.10% on Jul 14: Facts Behind the Movement

TradingKey
·
Jul 14

Eli Lilly price target raised to $1,385 from $1,300 at Bernstein

TIPRANKS
·
Jul 14

US Appeals Court Revives Teva Lawsuit over Lilly Osteoporosis Drug

Reuters
·
Jul 14

Eli Lilly Stock (LLY) Gets a Price Target Boost Heading into Earnings

TIPRANKS
·
Jul 14

UBS Adjusts Eli Lilly Price Target to $1,425 From $1,250, Maintains Buy Rating

MT Newswires Live
·
Jul 13

BMO Capital Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

TIPRANKS
·
Jul 13

Eli Lilly is Maintained at Buy by Guggenheim

Dow Jones
·
Jul 13

Guggenheim Adjusts PT on Eli Lilly and Co. to $1,273 From $1,235, Maintains Buy Rating

MT Newswires Live
·
Jul 13

Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Eli Lilly & Co (LLY)

TIPRANKS
·
Jul 13

Wells Fargo Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

TIPRANKS
·
Jul 12

Can AI Make Better Drugs? not on Wall Street's Timeline

Dow Jones
·
Jul 12

Eli Lilly & Co. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Jul 11

Eli Lilly is Maintained at Buy by B of a Securities

Dow Jones
·
Jul 11

Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says

MT Newswires Live
·
Jul 11